Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 18/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680270 | 1.00 | CETP (0.42) | CETPFFAR4CYP3A4TACR1 | |
| SCHEMBL680609 | 0.96 | CETP (0.42) | CETPCYP3A4TACR1 | |
| SCHEMBL680610 | 0.96 | CETP (0.42) | CETPCYP3A4TACR1 | |
| SCHEMBL13118711 | 0.96 | CETP (0.42) | CETPCYP3A4TACR1 | |
| Hydrochloric Acid SCHEMBL680534 | 0.96 | CETP (0.41) | CETPCYP3A4TACR1 | |
| Hydrochloric Acid SCHEMBL680533 | 0.96 | CETP (0.41) | CETPCYP3A4TACR1 | |
| SCHEMBL680808 | 0.94 | CETP (0.42) | CETP | |
| SCHEMBL680809 | 0.94 | CETP (0.42) | CETP | |
| Hydrochloric Acid SCHEMBL680399 | 0.94 | CETP (0.42) | CETP | |
| Hydrochloric Acid SCHEMBL680398 | 0.94 | CETP (0.42) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841478-B2 | Method for preparing trans-{4-[(alkylamino) methyl]- cyclohexyl}acetic acid ester | KOWA COMPANY, LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| EP-2383253-B1 | METHOD FOR MANUFACTURING TRANS-{4-[(ALKYL AMINO) METHYL]CYCLOHEXYL} ACETIC ESTER | KOWA CO (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-20110288328-A1 | METHOD FOR PREPARING TRANS-ACETIC ACID ESTER | KOWA COMPANY, LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-2383253-A1 | METHOD FOR MANUFACTURING TRANS-{4-Ý(ALKYL AMINO) METHYL¨CYCLOHEXYL} ACETIC ESTER | Kowa Company, Ltd. (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-7807701-B2 | Dibenzylamine compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-7807701-B2 | Dibenzylamine compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-7807701-B2 | Dibenzylamine compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. (JP) | 2008-06-19 | — | — | US | disclosed |
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. (JP) | 2008-06-19 | — | — | US | disclosed |
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. (JP) | 2008-06-19 | — | — | US | disclosed |
| US-7332514-B2 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2008-02-19 | — | — | US | disclosed |
| US-7332514-B2 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2008-02-19 | — | — | US | disclosed |
| US-7332514-B2 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2008-02-19 | — | — | US | disclosed |
| EP-1829858-A2 | Dibenzylamine compounds and pharmaceutical use thereof | Japan Tobacco, Inc. (JP) | 2007-09-05 | — | — | EP | disclosed |
| EP-1533292-B1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2007-02-14 | — | — | EP | disclosed |
| EP-1533292-A1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-05-25 | — | — | EP | disclosed |
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | CETP, CES1, APOB | CETP 1/4885FFAR4 557/4885CYP3A4 448/4885 |
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | CETP, PCSK9, CES1 | CETP 1/4885FFAR4 557/4885CYP3A4 356/4885 |
| US-20110288328-A1 | METHOD FOR PREPARING TRANS-ACETIC ACID ESTER | ACSL6, ACSL3, ACSL1 | CETP 274/4885FFAR4 392/4885CYP3A4 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.